The Global Atherectomy Devices Market size is expected to reach $900.7 million by 2025, rising at a market growth of 6.8% CAGR during the forecast period (2019-2025). The atherectomy procedure has been recognized as a minimally invasive surgical technique to remove atherosclerosis from blood vessels in the human body. This surgical procedure is a great replacement to angioplasty for treating peripheral artery disease. However, there are not enough studies to determine atherectomy’s superiority of angioplasty. It is also used for the treatment of coronary artery disease.

Atherectomy devices have been developed to allow the site of coronary occlusion or stenosis to drill, grind or sand atheroma, calcium, and excess cellular material. Mechanical approaches and laser-based methods are used extensively. To remove plaque from coronary arteries, the rotational atherectomy catheter (Rotablator) is engineered.

The key market players actively involved in the atherectomy devices market include Boston Scientific Corporation, Medtronic (Covidien), Cardiovascular Systems Inc., Spectranetics, Avinger Inc., Volcano Corporation, Koninklijke Philips N.V, ST. Jude Medical, Straub Medical AG, Cardinal Health (Cordis), BARD Peripheral Vascular, and Terumo IS. Market players are taking step-by-step approaches to leverage business possibilities. Companies focus on creative market-space competitive initiatives.

For example, in July 2018, Cardiovascular Systems signed an agreement with OrbusNeich for selling its coronary and peripheral Orbital Atherectomy Systems (OAS) in other countries. In the same month, the company collaborated with Aerolase Corporation for developing a new laser atherectomy device for physicians which can be used more effectively in the treatment of multiple forms of arterial disease.

In December 2015, Medtronic acquired Covidien to enhance its business in developing Atherectomy Device. In June 2017, Koninklijke Philips N.V. took over Spectranetics for expansion of image-guided therapy business group.

In March 2018, Terumo Corporation acquired assets related to the large bore vascular closure device from Medeon Biodesign, Inc. for enhancement of its product portfolio. In January 2019, Terumo IS expanded its reach to Canada by opening a new office in Vaughan, Ontario focusing on the expansion of its business.

The increased prevalence of target diseases is the major influential factor of the market. Over 250 million people across the globe suffer from peripheral artery disease (PAD), with an escalating geriatric population. Between 2000 and 2010, the incidence of PAD rose by 24% and continues to develop at an accelerating pace. This incidence is present in both high-and low-income nations. Low-income countries have seen a 29 percent raise, while high-income countries have seen a 13 percent raise over the past century.

Based on Type, the market is segmented into Directional Atherectomy, Rotational Atherectomy, Orbital Atherectomy and Laser Atherectomy. Based on Regions, the market is segmented into North America, Europe, Asia Pacific, and Latin America, Middle East & Africa.

Recent strategies deployed in Atherectomy Devices Market
Collaborations, Partnerships and Agreements:

  • Jul-2018: Cardiovascular Systems has collaborated with Aerolase Corporation for developing a new laser atherectomy device for physicians which can be used more effectively in the treatment of multiple form of arterial disease.
  • Jul-2018: Cardiovascular Systems has signed an agreement with OrbusNeich for selling its coronary and peripheral Orbital Atherectomy Systems (OAS) in other countries.
  • Nov-2016: Cardiovascular Systems has announced an agreement with Medikit Co., Ltd. in order to sell its Diamondback 360? Coronary and Peripheral Orbital Atherectomy Systems (OAS) in Japan.
  • Acquisition and Mergers:
  • Aug-2019: Cardiovascular Systems has acquired WIRION Embolic Protection System and related assets from Gardia Medical Ltd., a wholly owned Israeli subsidiary of Allium Medical Solutions Ltd. for use in any atherectomy system.
  • Aug-2019: Boston acquired BTG in order to develop products for vascular diseases.
  • Jan-2019: Abbott acquired Cephea Valve in order to expand the device portfolio to use in valve diseases.
  • Mar-2018: Terumo has acquired assets related to the large bore vascular closure device from Medeon Biodesign, Inc. for enhancement of its product portfolio.
  • Jun-2017: Philips has taken over Spectranetics for expansion of image-guided therapy business group.
  • Jan-2017: Abbott took over St. Jude Medical for expanding the product portfolio for treating the patients efficiently.
  • Dec-2015: Medtronic has acquired Covidien in order to enhance its business in developing Atherectomy Device.
  • Product launches:
  • Jul-2019: Avinger has launched Ocelot, image-guided chronic total occlusion (CTO) crossing system use in treatment of artery diseases.
  • Oct-2016: Avinger has introduced Lightbox Imaging Consolefirst-ever image-guided atherectomy and chronic total occlusion (CTO) recanalization devices for the treatment of artery diseases.

Scope of the Study
Market Segmentation:
By Type

  • Directional Atherectomy
  • Rotational Atherectomy
  • Orbital Atherectomy and
  • Laser Atherectomy



By Geography

  • North America
  • ·US
  • ·Canada
  • ·Mexico
  • ·Rest of North America
  • Europe
  • ·Germany
  • ·UK
  • ·France
  • ·Russia
  • ·Spain
  • ·Italy
  • ·Rest of Europe
  • Asia Pacific
  • ·China
  • ·India
  • ·Japan
  • ·South Korea
  • ·Singapore
  • ·Malaysia
  • ·Rest of Asia Pacific
  • LAMEA
  • ·Brazil
  • ·Argentina
  • ·UAE
  • ·Saudi Arabia
  • ·South Africa
  • ·Nigeria
  • ·Rest of LAMEA


Companies Profiled

  • Cardiovascular Systems, Inc.
  • Avinger, Inc.
  • Straub Medical AG
  • Boston Scientific Corporation
  • Medtronic PLC (Covidien)
  • Koninklijke Philips N.V.
  • Cardinal Health, Inc. (Cordis)
  • Terumo Corporation (Terumo IS)
  • Abbott Laboratories
  • B. Braun Melsungen AG


Unique Offerings from KBV Research

  • Exhaustive coverage
  • Highest number of market tables and figures
  • Subscription based model available
  • Guaranteed best price
  • Assured post sales research support with 10% customization free